Actinic keratosis outcomes can be affected by several variables, and these lesions need to be treated to minimize progression risk, noted Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.
Actinic keratosis outcomes can be affected by several variables, including chronic sun exposure, mutational burden, and immunosuppression. These concerning lesions need to be treated to minimize progression risk, noted Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.
Transcript
Why do 10% of patients with actinic keratosis develop skin cancer?
I think to reverse that question. If you're gonna say close to 90% of patients with actinic keratosis don't develop skin cancers, the other 10% do, or approximately. So, actinic keratoses are small keratotic lesions that develop typically on skin that has been chronically exposed to the sun—occurs a little more in our subpopulation that are older, more Caucasian, more males than females. These are lesions that are concerning, and they all should be treated to minimize the risk of progression. That's the main concern.
As far as who develops skin cancer and who doesn't, I think one thing that can be argued is that the amount of sun exposure someone's had over a lifetime can affect that. But since actinic keratoses and squamous cell carcinomas are tumors that rely on their mutational burden to develop tumors, which means a number of mutations or the types of mutations that are present—such as p53 or Notch mutations—in these tumors sort of determine what direction they're going to go in.
So I think more often than not it’s the morphology of the individual lesion that helps decide whether it's going to go toward cancer, and also the patient's level of immunosuppression. A patient who may be older, or may be on immunosuppressive therapy of one kind or another, may be a solid organ transplant recipient or other transplant, might have a higher risk as well. So I think it's a complex interplay between the tumor cells, the pending tumor cells in actinic keratosis, and the patient's immune response.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen